Patent expiration for key Wegovy ingredient could lead to $3 generics

By Allison Bell

News March 11, 2026 at 03:09 PM

Share & Print

What You Need To Know

By the end of 2026, semaglutide will lack patent protection in 160 countries.
About 84% of the obese people in the world live in those countries.
Manufacturing costs per person per year could be as low as $28 for injections and $186 for pills.

More From HR Executive

NOT FOR REPRINT

© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.